Operation Warp Speed’s Slaoui Ousted From Medical Company Board Over Misconduct Claim

Moncef Slaoui, seen last November in the White House Rose Garden, was a key figure in the Trump administrations crash program to develop COVID-19 vaccines.

Mandel Ngan/AFP by means of Getty Images

toggle caption

conceal caption

Mandel Ngan/AFP by means of Getty Images

Moncef Slaoui, seen last November in the White House Rose Garden, was a key figure in the Trump administrations crash program to develop COVID-19 vaccines.

Mandel Ngan/AFP through Getty Images

GSK stated it got a letter alleging that Slaoui sexually pestered and engaged in “unsuitable conduct” a number of years ago with a GSK worker. At the time of the supposed conduct, Slaoui was also a GSK staff member.

NPR attempted to reach Slaoui through Centessa Pharmaceuticals, where he is primary clinical consultant. The business did not make him available and decreased to comment.

” Dr. Slaouis behaviours are entirely undesirable,” GSK stated. “They represent an abuse of his management position, violate business policies, and contrast the strong values that specify GSKs culture.”

GSK said the examination is continuous.

Moncef Slaoui, who led the Trump administrations COVID-19 vaccine advancement efforts under Operation Warp Speed, has actually lost his job as chairman of the board at a medical gadget startup.

The business conducted an examination that corroborated the claims, GSKs declaration stated.

GlaxoSmithKline stated that it terminated Slaoui from Galvani Bioelectronics board of directors over claims of sexual harassment. Galvani is a medical research study company thats a joint venture in between GSK and Verily Life Sciences, an Alphabet company. GSK is the majority shareholder in the endeavor.

GlaxoSmithKline stated that it terminated Slaoui from Galvani Bioelectronics board of directors over allegations of sexual harassment. Galvani is a medical research study business thats a joint endeavor between GSK and Verily Life Sciences, an Alphabet company. GSK is the bulk investor in the venture.